Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study
R. F. M. Vermeulen(The Netherlands Cancer Institute), Neil K. Aaronson(The Netherlands Cancer Institute), E.B.L. van Dorst(Radboud University Nijmegen), Jacobien M. Kieffer(Norwegian Womens Public Health Association), Marc van Beurden(Oncode Institute), Leon F.A.G. Massuger(Radboud University Nijmegen), Eveline M. A. Bleiker(Cancer Clinic), Heiðdís Valdimarsdóttir(Reykjavík University), Katja N. Gaarenstroom(Radboud University Nijmegen), H.W.H.M. van der Putten(Maastricht University Medical Centre), Marian J.E. Mourits(Radboud University Nijmegen)
Cited by 50
Related Papers
Cross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries
|Journal of Clinical Epidemiology|1998|2.9k
EORTC QLQ-C30 Scoring Manual
|Research at the University of Copenhagen (University of Copenhagen)|1995|2.4k
Translation, Validation, and Norming of the Dutch Language Version of the SF-36 Health Survey in Community and Chronic Disease Populations
|Journal of Clinical Epidemiology|1998|2.3k
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
|New England Journal of Medicine|2018|1.4k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k